MGO One Seven LLC Acquires 3,042 Shares of Novartis AG (NYSE:NVS)

MGO One Seven LLC boosted its stake in shares of Novartis AG (NYSE:NVS - Free Report) by 12.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,710 shares of the company's stock after purchasing an additional 3,042 shares during the quarter. MGO One Seven LLC's holdings in Novartis were worth $2,696,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its holdings in shares of Novartis by 1.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 8,183,855 shares of the company's stock worth $796,372,000 after purchasing an additional 90,823 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Novartis by 16.0% during the 4th quarter. Renaissance Technologies LLC now owns 2,668,849 shares of the company's stock worth $259,706,000 after purchasing an additional 368,171 shares during the period. Fisher Asset Management LLC increased its holdings in shares of Novartis by 17.4% during the 4th quarter. Fisher Asset Management LLC now owns 2,002,959 shares of the company's stock worth $194,908,000 after purchasing an additional 296,950 shares during the period. Chevy Chase Trust Holdings LLC increased its holdings in shares of Novartis by 4.7% during the 4th quarter. Chevy Chase Trust Holdings LLC now owns 1,161,139 shares of the company's stock worth $112,990,000 after purchasing an additional 52,044 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Novartis during the 4th quarter worth about $88,339,000. Institutional investors own 13.12% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on NVS shares. Barclays restated an "underweight" rating on shares of Novartis in a report on Monday, February 3rd. BNP Paribas upgraded shares of Novartis to a "strong-buy" rating in a research report on Tuesday, April 15th. Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a "hold" rating to a "buy" rating in a research report on Tuesday, February 4th. StockNews.com upgraded shares of Novartis from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 8th. Finally, Morgan Stanley initiated coverage on shares of Novartis in a research report on Wednesday, February 12th. They set an "underweight" rating on the stock. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $123.38.

Novartis Price Performance

NYSE:NVS traded up $1.89 on Tuesday, reaching $114.52. The stock had a trading volume of 1,442,084 shares, compared to its average volume of 1,547,510. The company has a market capitalization of $241.90 billion, a P/E ratio of 19.48, a price-to-earnings-growth ratio of 1.70 and a beta of 0.56. Novartis AG has a 1-year low of $96.06 and a 1-year high of $120.92. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The stock has a fifty day moving average price of $109.79 and a 200-day moving average price of $106.07.

Novartis (NYSE:NVS - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $2.28 earnings per share for the quarter, topping analysts' consensus estimates of $2.12 by $0.16. Novartis had a net margin of 23.56% and a return on equity of 37.24%. The company had revenue of $13.23 billion during the quarter, compared to the consensus estimate of $12.92 billion. During the same period in the previous year, the firm posted $1.80 earnings per share. The company's revenue was up 11.9% on a year-over-year basis. Research analysts forecast that Novartis AG will post 8.45 EPS for the current year.

Novartis Announces Dividend

The business also recently announced a dividend, which was paid on Wednesday, March 12th. Shareholders of record on Wednesday, March 12th were paid a $3.8695 dividend. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis's dividend payout ratio is presently 44.05%.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.